Trajectories of disease evolution upon treatment initiation in systemic lupus erythematosus: results from four clinical trials of belimumab

Systemic Lupus Erythematosus

LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials

Ann Rheum Dis

Morand EF, van Vollenhoven R, Furie RA, Kalunian KC, Manzi S, Abreu G, Tummala R, Duncan EA, Al-Mossawi H, Lindholm C

doi: 10.1016/j.ard.2025.01.016

Systemic Lupus Erythematosus

Treatment of systemic lupus erythematosus: Analysis of treatment patterns in adult and paediatric patients across four European countries

Eur J Intern Med

Du M, Dernie F, Català M, Delmestri A, Man WY, Brash JT, van Ballegooijen H, Mercadé-Besora N, Duarte-Salles T, Mayer MA, Leis A, Ramírez-Anguita JM, Griffier R, Verdy G, Prats-Uribe A, Pacurariu A, Morales DR, De Lisa R, Galluzzo S, Egger GF, Prieto-Alhambra D, Tan EH

doi: 10.1016/j.ejim.2024.08.008

Systemic Lupus Erythematosus

Clinical Presentation, Care Pathways, and Delays in Access to Specialized Care in Patients With Systemic Lupus Erythematosus: A Study From Lupus Midwest Network (LUMEN 💡)

Arthritis Care Res (Hoboken)

Sanchez-Rodriguez A, Meade-Aguilar JA, Yang JX, Figueroa-Parra G, Hanson AC, Langenfeld HE, Thanarajasingam U, Chamberlain AM, Greenlund KJ, Barbour KE, Crowson CS, Duarte-García A

doi: 10.1002/acr.25445

Systemic Lupus Erythematosus

Use of belimumab in treating patients with systemic lupus erythematosus: a single-center, real-world retrospective study

Arthritis Res Ther

Su Z, Zhang C, Gao C, Li C, Li R, Zheng Z

doi: 10.1186/s13075-024-03389-4

Systemic Lupus Erythematosus

Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study

Ann Rheum Dis

Aranow C, Allaart CF, Amoura Z, Bruce IN, Cagnoli PC, Chatham WW, Clark KL, Furie R, Groark J, Urowitz MB, van Vollenhoven R, Daniels M, Fox NL, Gregan YI, Henderson RB, van Maurik A, Ocran-Appiah JC, Oldham M, Roth DA, Shanahan D, Tak PP, Teng YO

doi: 10.1136/ard-2024-225686

Systemic Lupus Erythematosus

Efficacy and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors for the Primary Prevention of Cardiovascular, Renal Events and Safety Outcomes in Patients with Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes: A Population-based Target Trial Emulation

Arthritis Rheumatol

Ma KS, Lo JE, Kyttaris VC, Tsokos GC, Costenbader KH

doi: 10.1002/art.43037

Rheumatoid Arthritis

Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial

Ann Rheum Dis

Lend K, Lampa J, Padyukov L, Hetland ML, Heiberg MS, Nordström DC, Nurmohamed MT, Rudin A, Østergaard M, Haavardsholm EA, Hørslev-Petersen K, Uhlig T, Sokka-Isler T, Gudbjornsson B, Grondal G, Frazzei G, Christiaans J, Wolbink G, Rispens T, Twisk JWR, van Vollenhoven RF

doi: 10.1136/ard-2024-226024

Systemic Lupus Erythematosus

Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials

Ann Rheum Dis

Baker T, Sharifian H, Newcombe PJ, Gavin PG, Lazarus MN, Ramaswamy M, White WI, Ferrari N, Muthas D, Tummala R, Morand EF, Furie R, Vital EM, Chamberlain C, Platt A, Al-Mossawi H, Brohawn PZ, Csomor E

doi: 10.1136/ard-2023-225445

Immunodeficiency

Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study

J Clin Immunol

Rubinstein A, Mabudian M, McNeil D, Patel NC, Wasserman RL, Gupta S, Carrasco P, Chen J, Garcia E, Nagy A, Yel L

doi: 10.1007/s10875-024-01769-8

Related content

LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials

Treatment of systemic lupus erythematosus: Analysis of treatment patterns in adult and paediatric patients across four European countries

Clinical Presentation, Care Pathways, and Delays in Access to Specialized Care in Patients With Systemic Lupus Erythematosus: A Study From Lupus Midwest Network (LUMEN 💡)

Use of belimumab in treating patients with systemic lupus erythematosus: a single-center, real-world retrospective study

Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study

Efficacy and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors for the Primary Prevention of Cardiovascular, Renal Events and Safety Outcomes in Patients with Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes: A Population-based Target Trial Emulation

Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial

Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials

Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study